Current status and future perspectives of liquid biopsy in non-small cell lung cancer
With advances in target therapy, molecular analysis of tumors is routinely required for treatment decisions in patients with advanced non-small cell lung cancer (NSCLC). Liquid biopsy refers to the sampling and analysis of circulating cell-free tumor DNA (ctDNA) in various body fluids, primarily blo...
Saved in:
Main Authors: | Sunhee Chang (Author), Jae Young Hur (Author), Yoon-La Choi (Author), Chang Hun Lee (Author), Wan Seop Kim (Author) |
---|---|
Format: | Book |
Published: |
Korean Society of Pathologists & the Korean Society for Cytopathology,
2020-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Liquid biopsy using extracellular vesicle-derived DNA in lung adenocarcinoma
by: In Ae Kim, et al.
Published: (2020) -
Liquid biopsy in CNS tumors: Current status & future perspectives
by: Nuzhat Husain, et al.
Published: (2022) -
Future directions and management of liquid biopsy in non-small cell lung cancer
by: Alessia Maria Cossu, et al.
Published: (2020) -
Liquid Biopsy: Current Status and Future Perspective in Gastric Cancer and Helicobacter Infection
by: Eun A Kang, et al.
Published: (2018) -
Molecular biomarker testing for non-small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
by: Sunhee Chang, et al.
Published: (2021)